Group 1 - Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange on January 22, with CITIC Securities International as the sole sponsor [1] - The company is a biotechnology firm nearing commercialization, focusing on oncology and autoimmune diseases [1] - Bangshun Pharmaceutical has established a pipeline that includes one drug candidate in the New Drug Application (NDA) stage (Bezafibrate), one drug candidate in the registration clinical stage (CX1440), and five drug candidates in the preclinical stage (CX03, CX12, CX13, CX15, and CX16) [1]

Group 1 - The core viewpoint of the article is that Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - Bangshun Pharmaceutical is a biotechnology company nearing commercialization, focusing on oncology and autoimmune diseases [1] - The company has established a pipeline that includes one new drug application candidate (Bezeqitinib), one clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hangzhou Bangshun Pharmaceutical Co., Ltd. 杭州邦順製藥股份有限公司 (the "Company") (A joint stock company established in the P ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Hangzhou Bangshun Pharmaceutical Co., Ltd. 重要提示：閣下如對本文件的任何內容有任何疑問，應徵詢獨立專業意見。 杭州邦順製藥股份有限公司 （「本公司」） （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員 表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據呈交香港公司註冊處處 長註冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的 ...